Oxaliplatin: Role in the treatment of metastatic colorectal cancer;Place et interet de l'oxaliplatine dans les cancers colorectaux metastases

Revue de Medecine Interne

Volumn 18, Issue SUPPL. 4, 1997, Pages

  Louvet, C ^a   De Gramont, A ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

5 FU; Advanced colorectal cancer; Oxaliplatin

Indexed keywords

FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADJUVANT THERAPY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERANCE; HUMAN; METASTASIS; PHASE 1 CLINICAL TRIAL; COLORECTAL TUMOR; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 0030848574     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(97)83767-8     Document Type: Conference Paper

References (16)

1. Mathé G, Kidani Y, Triana K et al. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (L-OHP). Biomed & Pharmacother 1986;40:372-6
2. Jennerwein MM, Eastman A, Khokhar A. Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexane-platinum complexes. Chem Biol Interactions 1989;70:39-49
3. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diamino-cyclo-hexane) platinum (II), new experimental data. Biomed & Pharmacother 1989;43:251-60
4. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein, binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res 1993;53:5970-6
5. Kraker AJ, Moore CW. Accumulation of cis-diaminedichloro-platinum and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res 1988;48:9-13
6. Raymond E, Djelloul C, Buguet-Fagot C. Oxaliplatin (LOHP) and cisplatin (CDDP) in combination with 5FU, specific thymidilate synthase (15) inhibitors (AG337, ZD1694), and topoisomerase I (topo-I) inhibitors (SN38, CPT-11) in human colonic, ovarian and breast cancers. Proc Am Ass Cancer Res 1996 [Abstract 1981]
7. Mathé G, Kidani Y, Segiguchi M et al. Oxalatoplatirium or 1-OHP, a third generation platinum complex, an experimental and clinical apraisal and preliminary comparison with cisplatin and carboplatinum. Biomed & Pharmacother 1989;43:237-50
8. Extra JM, Espié M, Calvo F et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299-303
9. Massari C, Brienza S, Rotarski M et al. Oxaliplatin comparative pharmacokinetics in normal and impaired renal function patients. Proc Am Ass Cancer Res 1996 [Abstract 1445]
10. Gamelin E, Allain P, Boisdron M et al. Pharmacokinetic behavior of oxaliplatin in repeated administration. Proc Am Ass Cancer Res 1996 [Abstract 2516]
11. Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-8
12. Lévi F, Misset JL, Brienza S et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992;69:893-900
13. Lévi F, Perpoint B, Garufi C et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 9:1280-4
14. Louvet C, Bleiberg H, Gamelin E et al. Oxaliplatin (L-OHP) synergistic clinical activity with 5FU in FU resistant colorectal cancer patients is independent of 5FU ± folinic acid schedule. Proc Am Soc Clin Oncol 1996; 15 [Abstract 467]
15. de Gramont A, Vignoud J, Toumigand C et al. Oxaliplatin with high-dose Leucovorin and 5-Fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-9
16. Brienza S, Vignoud J, Itzahki M, Krikorian A. Oxaliplatin (L-OHP): global safety in 682 patients. Eur J Cancer 1995:31 A [Abstract 933]